Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor relebactam – has been cleared by the FDA for adults with ...

MSD took a similar approach with its Recarbrio (imipenem/cilastatin-relebactam) product, which was approved by the FDA for cUTIs and complicated intra-abdominal infections (cIAI) in 2019.

You can now play an even larger range of puzzles on our site, every weekday and now also every Saturday. Check out our brand new puzzles below, from Hangman to Add Up and even a Jigsaw. Of course ...